Search Result

Results for "

Huntington

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adenosine Receptor (2) Adrenergic Receptor (1) Akt (5) AMPK (1) Amyloid-β (5) Apoptosis (20) Atg8/LC3 (3) ATP Synthase (1) Autophagy (8) Biochemical Assay Reagents (1) Calcium Channel (2) Calpain (1) Cannabinoid Receptor (1) Carnitine Palmitoyltransferase (CPT) (1) Caspase (14) CD47 (1) CD74 (1) COX (1) DNA/RNA Synthesis (2) Dopamine Receptor (5) Drug Derivative (2) Drug Intermediate (1) Drug Metabolite (1) Dynamin (5) DYRK (1) Endogenous Metabolite (6) Environmental Pollutants (2) Epigenetic Reader Domain (1) ERK (3) Eukaryotic Initiation Factor (eIF) (1) Fluorescent Dye (1) GABA Receptor (11) Glucocorticoid Receptor (2) Glutaminase (3) Glutathione Reductase (GR) (1) GPR6 (1) GSK-3 (1) HDAC (4) Heme Oxygenase (HO) (2) Histamine Receptor (4) Histone Demethylase (2) HSP (2) Huntingtin (19) iGluR (4) Interleukin Related (1) Isotope-Labeled Compounds (10) Keap1-Nrf2 (1) KMO (2) Ligands for Target Protein for PROTAC (1) mAChR (1) Mas-related G-protein-coupled Receptor (MRGPR) (1) mGluR (1) Mitochondrial Metabolism (6) Monoamine Oxidase (1) Monoamine Transporter (11) nAChR (1) NF-κB (1) Orexin Receptor (OX Receptor) (1) P-glycoprotein (1) p38 MAPK (2) Parasite (2) PARP (2) PERK (1) PI3K (1) PI5P4K (1) Potassium Channel (2) PROTACs (1) Reference Standards (11) RIP kinase (1) ROCK (1) Sirtuin (8) SOD (1) Sodium Channel (2) Tau Protein (1) TNF Receptor (1) Transmembrane Glycoprotein (1) Trk Receptor (2) TRP Channel (1) α-synuclein (4)
By Research Areas:	Cancer (19) Cardiovascular Disease (4) Endocrinology (2) Infection (3) Inflammation/Immunology (21) Metabolic Disease (9) Neurological Disease (116)
Click Chemistry:	Alkynes (1)
Oligonucleotides:	Cationic Lipids (1) Antisense Oligonucleotides (5)

126

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-15452

Selisistat Maximum Cited Publications 292 Publications Verification EX-527	Sirtuin	Inflammation/Immunology Cancer
Selisistat (EX-527) is a potent and selective SirT1 (Sir2 in Drosophila melanogaster) inhibitor with an IC₅₀ of 123 nM for SirT1. Selisistat alleviates pathology in multiple animal and cell models of Huntington's disease .

HY-N0303

Idebenone 5+ Cited Publications	Mitochondrial Metabolism Apoptosis	Neurological Disease
Idebenone, a well-appreciated mitochondrial protectant, exhibits protective efficacy against neurotoxicity and can be used for the research of Alzheimer's disease, Huntington's disease. Idebenone (oxidised form) has a dose-dependent inhibitory effect on the enzymatic metabolism of arachidonic acid in astroglial homogenates (IC₅₀=16.65 μM) . Idebenone, a coenzyme Q10 analog and an antioxidant, induces apoptotic cell death in the human dopaminergic neuroblastoma SHSY-5Y cells . Idebenone quickly crosses the blood-brain barrier.

HY-15262

SRT 2104 20+ Cited Publications	Sirtuin	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
SRT 2104 is a first-in-class, highly selective and brain-permeable activator of the NAD ⁺ dependent deacetylase Sirt1, increases Sirt1 protein, but shows no effect on Sirt1 mRNA. Used in the research of diabetes mellitus and Huntington’s disease .

HY-143218

TPE-MI 10+ Cited Publications Tetraphenylethene maleimide	Huntingtin Parasite	Infection Neurological Disease
TPE-MI (Tetraphenylethene maleimide) is a thiol probe for measuring unfolded protein load and proteostasis in cells (the excitation wavelength is 350 nm and the emission wavelength is 470 nm). TPE-MI can report imbalances in proteostasis in induced pluripotent stem cell models of Huntington disease, as well as cells transfected with mutant Huntington exon 1 before the formation of visible aggregates. TPE-MI also detects protein damage following dihydroartemisinin research of the malaria parasites Plasmodium falciparum .

HY-16771

Valbenazine 4 Publications Verification NBI-98854	Monoamine Transporter	Neurological Disease
Valbenazine (NBI-98854) is a vesicular monoamine transporter 2 (VMAT2) inhibitor with the K_i of 110-190 nM .

HY-B0349

Meclizine dihydrochloride 4 Publications Verification Meclozine dihydrochloride	Histamine Receptor Apoptosis	Neurological Disease Endocrinology Cancer
Meclizine (Meclozine) dihydrochloride, an antihistamine, reversibly inhibits the interaction of histamine at the H1 receptors. Meclizine dihydrochloride is a member of the piperazine class of H1 antagonists. Meclizine dihydrochloride is an effective anti-motion sickness agent. Meclizine dihydrochloride crosses the blood-brain barrier. Meclizine dihydrochloride can be used for the research of polyQ toxicity disorders, such as Huntington's disease. Meclizine dihydrochloride is an agonist ligand for mouse constitutive androstane receptor (CAR) and an inverse agonist for Human CAR .

HY-B0590

Tetrabenazine 1 Publications Verification Ro 1-9569	Monoamine Transporter Dopamine Receptor	Neurological Disease
Tetrabenazine (Ro 1-9569) is a brain-penetrant and orally active VMAT2-selective ligand with human VMAT2 K_i 100 nM. Tetrabenazine binds VMAT2 to block monoamine uptake into synaptic vesicles, potentiates cytoplasmic monoamine degradation. Tetrabenazine weakly blocks dopamine D2 receptors, and increases dopamine turnover via elevated cerebrospinal fluid homovanillic acid. Tetrabenazine can be used for the research of Huntington’s disease, tardive dyskinesia, and Tourette’s syndrome .

HY-124476

Cystamine 5 Publications Verification	Caspase Glutaminase Apoptosis	Cancer
Cystamine is the disulfide form of the free thiol, cysteamine. Cystamine is an orally active transglutaminase (Tgase) inhibitor. Cystamine also has inhibition activity for caspase-3 with an IC₅₀ value of 23.6 μM. Cystamine can be used for the research of severals diseases including Huntington's disease (HD) .

HY-N10546

Ganglioside GM1	iGluR Trk Receptor ERK Apoptosis Autophagy	Neurological Disease
Ganglioside GM1 is a type of glycosphingolipid, mainly found on the cell membranes of the central nervous system of vertebrates. Ganglioside GM1 exerts neuroprotective effects by reducing excessive activation of NMDAR, activating TrkA and ERK1/2, and inhibiting oxidative stress and cell apoptosis and autophagy. Ganglioside GM1 can be used in the research of diseases such as traumatic brain injury, Parkinson's disease, Alzheimer's disease, and Huntington's disease .

HY-B0590S

Tetrabenazine-d6 Ro 1-9569-d₆	Monoamine Transporter	Neurological Disease
Tetrabenazine-d₆ (Deutetrabenazine) is a deuterium-labled Tetrabenazine (HY-B0590). Tetrabenazine (Ro 1-9569) is a brain-penetrant and orally active VMAT2-selective ligand with human VMAT2 K_i 100 nM. Tetrabenazine binds VMAT2 to block monoamine uptake into synaptic vesicles, potentiates cytoplasmic monoamine degradation. Tetrabenazine weakly blocks dopamine D2 receptors, and increases dopamine turnover via elevated cerebrospinal fluid homovanillic acid. Tetrabenazine can be used for the research of Huntington’s disease, tardive dyskinesia, and Tourette’s syndrome .

HY-16482

Teglicar 3 Publications Verification	Carnitine Palmitoyltransferase (CPT) Endogenous Metabolite	Neurological Disease Metabolic Disease
Teglicar is a selective and reversible orally active liver isoform of carnitine palmitoyl-transferase 1 (L-CPT1) inhibitor with an IC₅₀ value of 0.68 μM and a K_i value of 0.36 μM. Teglicar has a potential antihyperglycemic propert. Teglicar can be used for the research of diabetes and neurodegenerative disease including Huntington's disease (HD) .

HY-14569

CDPPB 1 Publications Verification	mGluR Akt ERK Caspase Mitochondrial Metabolism	Neurological Disease Inflammation/Immunology Cancer
CDPPB is a selective, orally active and brain-penetrant mGluR5 allosteric modulator. CDPPB increases AKT and ERK1/2 activation and augments the BDNF mRNA. CDPPB inhibits caspase-3 activation and mitochondrial dysfunction. CDPPB improves cognitive impairment, depression, and Huntington's disease .

HY-N2099

Onjisaponin B 2 Publications Verification Senegin III	Autophagy Amyloid-β Caspase NF-κB Apoptosis	Neurological Disease Metabolic Disease Inflammation/Immunology
Onjisaponin B is an orally active natural product derived from Polygala tenuifolia. Onjisaponin B inhibits NF-κB p65. Onjisaponin B enhances autophagy and accelerates the degradation of mutant α-synuclein and huntingtin. Onjisaponin B reduces β-amyloid (Aβ) production. Onjisaponin B reduces radiation-induced cell apoptosis. Onjisaponin B has anti-oxidant and anti-inflammatory activities. Onjisaponin B can be used for neurological disease and radiation injury study, and its metabolite tenuifolin (TF) can enter the brain through the BBB .

HY-B0248

Desonide 2 Publications Verification	Glucocorticoid Receptor Huntingtin Apoptosis	Neurological Disease Inflammation/Immunology
Desonide is a non-fluorinated corticosteroid anti-inflammatory agent that acts on the glucocorticoid receptor. Desonide can also specifically bind to the mutant huntingtin protein (mHTT), reducing the level and toxicity of mHTT. Desonide can be used in the research of Huntington's disease and inflammatory diseases such as atopic dermatitis .

HY-W020050

Cystamine dihydrochloride 5 Publications Verification	Caspase Glutaminase Apoptosis	Neurological Disease Cancer
Cystamine (dihydrochloride) is the disulfide form of the free thiol, cysteamine. Cystamine is an orally active transglutaminase (Tgase) inhibitor. Cystamine also has inhibition activity for caspase-3 with an IC₅₀ value of 23.6 μM. Cystamine can be used for the research of severals diseases including Huntington's disease (HD) .

HY-130259

LC3-mHTT-IN-AN2	Atg8/LC3 Autophagy	Neurological Disease
LC3-mHTT-IN-AN2 (Compound AN2) is a mHTT-LC3 linker compound, which interacts with both mutant huntingtin protein (mHTT) and LC3B but not with wtHTT or irrelevant control proteins. LC3-mHTT-IN-AN2 reduces the levels of mHTT in an allele-selective manner in cultured Huntington disease (HD) mouse neurons .

HY-137207

MK-28 5+ Cited Publications	PERK	Neurological Disease
MK-28 is a potent and selective PERK activator. MK-28 exhibits remarkable pharmacokinetic properties and high BBB penetration in mice .

HY-136311

NCT-504	PI5P4K	Neurological Disease
NCT-504 is a selective allosteric inhibitor of PIP4Kγ, with an IC₅₀ of 15.8 μM. NCT-504 is potential for the research of Huntington's disease .

HY-130258

LC3-mHTT-IN-AN1	Atg8/LC3 Autophagy	Neurological Disease
LC3-mHTT-IN-AN1 (Compound AN1) is a mHTT-LC3 linker compound, which interacts with both mutant huntingtin protein (mHTT) and LC3B but not with wtHTT or irrelevant control proteins. LC3-mHTT-IN-AN1 reduces the levels of mHTT in an allele-selective manner in cultured Huntington disease (HD) mouse neurons .

HY-156650

Votoplam PTC518	Huntingtin	Neurological Disease
Votoplam (PTC518) (Example 37) is an HTT gene regulator with an IC₅₀ ≤ 0.1 μM. Votoplam can be used in the research of Huntington's disease .

HY-142035

N-Propargylglycine 1 Publications Verification	Mitochondrial Metabolism	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
N-Propargylglycine is a brain-penetrant and orally active PRODH inhibitor. N-Propargylglycine covalently modifies enzyme-bound FAD and active site lysine, causing enzyme structural distortion, protein decay, and irreversible inhibition of proline and 4-hydroxyproline catabolism. N-Propargylglycine induces UPRmt, upregulates mitochondrial chaperones and YME1L1, enhances mitochondrial proteostasis, blocks astrocytic L-proline consumption, and abolishes L-proline’s ATP-maintaining and viability-protective effects. N-Propargylglycine stimulates neural processes, increases brain proline, hydroxyproline, and sarcosine levels, partially normalizes Huntington’s disease whole brain transcriptomes. N-Propargylglycine reduces hyperoxaluria, prevents calcium oxalate stone formation, reduces kidney tubular damage, and restores weight and survival in Grhpr knockout mice. N-Propargylglycine can be used for the research of breast cancer, neurodegenerative disorders, Huntington’s disease, and primary hyperoxaluria type 2 .

HY-100384

NKL 22 1 Publications Verification	HDAC	Neurological Disease Cancer
NKL 22 is a potent and selective inhibitor of histone deacetylases (HDAC), with IC₅₀ values of 199 and 69 nM for HDAC1 and HDAC3, respectively. NKL 22 can reverse abnormal expression of HD‑related genes and restore the levels of key genes including Ppp1r1b in Huntington's disease transgenic mice. NKL 22 can be used for the researches of Huntington's disease and cancer .

HY-136833

X5050 4 Publications Verification	DNA/RNA Synthesis	Neurological Disease
X5050 is a REST inhibitor, with an EC₅₀ of 2.1 μM .

HY-136780

SEN177	Amyloid-β Apoptosis CD47 Huntingtin	Neurological Disease Cancer
SEN177 is an orally effect glutamine cyclase (QC) inhibitor. The K_i of SEN177 for human glutamine cyclase (hQC) is 20 nM, and the IC₅₀ is 13 nM. SEN177 interferes with the interaction between CD47 and SIRRPα, and has anti-tumor activity. SEN177 reduces aggregation and apoptosis caused by HTT mutation in Huntington model, and can be used in the study of neurodegenerative diseases .

HY-W019710

(E,E)-RGFP966	HDAC	Neurological Disease
(E,E)-RGFP966 is a selective and CNS permeable HDAC3 inhibitor that can be used for the research of Huntington’s disease .

HY-132579

Tominersen RG6042; IONIS-HTTRx	Huntingtin	Neurological Disease
Tominersen (RG6042) is a second-generation 2′-O-(2-methoxyethyl) antisense oligonucleotide that targets huntingtin protein (HTT) mRNA and potently suppresses HTT production. Tominersen improves survival and reduces brain atrophy in mice. Tominersen can be used for the research of Huntington’s disease (HD) .

HY-B0590A

Tetrabenazine Racemate Ro 1-9569 Racemate	Monoamine Transporter Dopamine Receptor	Neurological Disease
Tetrabenazine (Ro 1-9569) Racemate is a brain-penetrant and orally active VMAT2-selective ligand with human VMAT2 K_i 100 nM. Tetrabenazine Racemate binds VMAT2 to block monoamine uptake into synaptic vesicles, potentiates cytoplasmic monoamine degradation. Tetrabenazine Racemate weakly blocks dopamine D2 receptors, and increases dopamine turnover via elevated cerebrospinal fluid homovanillic acid. Tetrabenazine Racemate can be used for the research of Huntington’s disease, tardive dyskinesia, and Tourette’s syndrome .

HY-107660

SIRT2-IN-8	Sirtuin	Neurological Disease
SIRT2-IN-8 is a potent SIRT2 inhibitor. SIRT2-IN-8 can be used for Huntington’s and Parkinson’s diseases research .

HY-150640

Rho-Kinase-IN-2	ROCK	Neurological Disease Inflammation/Immunology Cancer
Rho-Kinase-IN-2 (Compound 23) is an orally active, selective, and CNS-penetrant Rho Kinase (ROCK) inhibitor (ROCK2 IC₅₀ = 3 nM). Rho-Kinase-IN-2 can be used in Huntington’s research .

HY-132579A

Tominersen sodium RG6042 sodium; IONIS-HTTRx sodium	Huntingtin	Neurological Disease
Tominersen sodium is a second-generation 2′-O-(2-methoxyethyl) antisense oligonucleotide that targets huntingtin protein (HTT) mRNA and potently suppresses HTT production. Tominersen improves survival and reduces brain atrophy in mice. Tominersen sodium can be used for the research of Huntington’s disease (HD) .

HY-P6374

IIQLPEIVVV TFA	Dynamin	Neurological Disease
IIQLPEIVVV TFA is a specific inhibitor of Drp1-Mff interaction. IIQLPEIVVV TFA can distinguish physiological from pathological fission and block physiological fission, thus leading to mitochondrial dysfunction. IIQLPEIVVV TFA can be used in the study of Huntington's disease .

HY-177360

RNA splicing modulator-4	DNA/RNA Synthesis	Neurological Disease Cancer
RNA splicing modulator-4 is an RNA splicing modulator. RNA splicing modulator-4 controls the inclusion or exclusion of specific exons in precursor mRNA (pre-mRNA) by regulating alternative splicing events, thereby altering the coding sequence and function of mature mRNA. RNA splicing modulator-4 shows promise for research into neurodegenerative diseases (such as Huntington's disease) and cancers .

HY-D0193A

Ponceau 4R (85%) Acid Red 18 (85%); New Coccine (85%)	Environmental Pollutants Drug Derivative	Neurological Disease Inflammation/Immunology
Ponceau 4R (85%) (Acid Red 18 (85%); New Coccine (85%)) is an orally active synthetic food colorant and a HSA-binding aggregator. Ponceau 4R (85%) binds to HSA, inducing its partial unfolding, conformational changes and aggregation. Ponceau 4R (85%) serves as a food colorant and can be used in research on diseases including type Ⅱ diabetes, Parkinson's disease, Huntington's disease and spongiform encephalopathy .

HY-103333

Arvanil N-Vanillylarachidonamide	TRP Channel Cannabinoid Receptor CD74 Akt Orexin Receptor (OX Receptor)	Neurological Disease Inflammation/Immunology
Arvanil (N-Vanillylarachidonamide) is a mixed agonist of CB1 and TRPV1 receptors. Arvanil downregulates CD25, HLA-DR, CD134/OX40, blocks G1/S phase transition, and induces phosphorylation of Akt. Arvanil does not induce apoptosis in cells. Arvanil inhibits lymphocyte activation and ameliorates autoimmune encephalomyelitis. Arvanil can be used in research related to Huntington's disease, vomiting, and multiple sclerosis .

HY-108312A

Ac-VEID-CHO TFA	Caspase	Neurological Disease
Ac-VEID-CHO (TFA) is a peptide-derived caspase inhibitor and has potency of inhibition for Caspase-6, Caspase-3 and Caspase-7 with IC₅₀ values of 16.2 nM, 13.6 nM and 162.1 nM, respectively. Ac-VEID-CHO (TFA) can be used for the research of neurodegenerative conditions including Alzheimer’s and Huntington’s disease .

HY-147060

Dyrk1A-IN-3	DYRK	Neurological Disease
Dyrk1A-IN-3 (Compound 8b), a highly selective dual-specificity tyrosine-regulated kinase 1A (DYRK1A) inhibitor, maintains high levels of DYRK1A binding affinity (IC₅₀=76 nM). Dyrk1A-IN-3 can be used for the research of neurodegenerative disorders such as Alzheimer’s Disease, Huntington’s Disease, and Parkinson’s Disease .

HY-16771A

Valbenazine tosylate 4 Publications Verification NBI-98854 tosylate	Monoamine Transporter	Neurological Disease
Valbenazine tosylate (NBI-98854 tosylate) is a vesicular monoamine transporter 2 (VMAT2) inhibitor with the K_i of 110-190 nM .

HY-P11005

P259	Dynamin ATP Synthase	Neurological Disease
P259 is a Drp1-Mff inhibitor. P259 distinguishes physiological from pathological fission by specifically inhibiting Drp1-Mff interaction. P259 elongates cell mitochondria and disrupts mitochondrial function and motility. P259 reduces ATP levels and alters mitochondrial structure in the brain, resulting in behavioral deficits in wild-type mice and a short lifespan in Huntington's disease (HD) mice model .

HY-B1899S

Taurodeoxycholic acid-d5 Taurodeoxycholate-d₅	Isotope-Labeled Compounds Endogenous Metabolite Apoptosis	Others
Taurodeoxycholic acid-d₅ is the deuterium labeled Taurodeoxycholic acid (HY-B1899) . Taurodeoxycholic acid, a bile acid, stabilizes the mitochondrial membrane, decreases free radical formation. Taurodeoxycholic acid inhibits apoptosis by blocking a calcium-mediated apoptotic pathway as well as caspase-12 activation. Taurodeoxycholic acid exhibits neuroprotective effect in 3-nitropropionic acid induced mouse model or genetic mouse model of Huntington's disease (HD) .

HY-W004425

DMPX 3,7-Dimethyl-1-propargylxanthine	Adenosine Receptor	Neurological Disease
DMPX (3,7-Dimethyl-1-propargylxanthine) is a selective A_2A adenosine receptor (A_2A AR) antagonist that crosses the blood-brain barrier, with a K_i of 11 μM for rat A₂ adenosine receptor and a K_i of 45 μM for rat A₁ adenosine receptor. By blocking A2A receptors in specific brain regions, DMPX protects dopaminergic and GABAergic neurons from mitochondrial dysfunction. DMPX is applicable to research related to depression, Parkinson's disease and Huntington's disease .

HY-111560

IQM-266	Potassium Channel	Neurological Disease
IQM-266 is a Downstream Regulatory Element Antagonist Modulator (DREAM) ligand with a K_D of 4.63 μM. IQM-266 inhibits the K_V4.3/DREAM current in a concentration-, voltage-, and time-dependent-manner. IQM-266 also modulates A-type outward potassium currents (IA) from rat dorsal root ganglia (DRG) neurons. IQM-266 can be used for neurological disease research, such as Alzheimer’s disease and Huntington's disease (HD) .

HY-132593

Rovanersen WVE-120101	Huntingtin	Neurological Disease
Rovanersen (WVE-120101) is an antisense oligonucleotide that specifically targets mutated mRNA copies of the huntington (HTT) gene without affecting healthy mRNA of HTT gene, thereby preventing the production of faulty Huntingtin protein. Rovanersen can be used for huntington’s disease research .

HY-G0025

Tetrabenazine Metabolite (-)-β-Dihydrotetrabenazine; (-)-β-HTBZ	Monoamine Transporter Drug Metabolite	Neurological Disease
Tetrabenazine Metabolite is an active metabolite of Tetrabenazine. Tetrabenazine Metabolite is a vesicular monoamine transporter 2 (VMAT2) inhibitor with a high affinity (K_i=13.4 nM) . Tetrabenazine Metabolite is be developed for the treatment of chorea associated with Huntington’s disease and other hyperkinetic disorders .

HY-148624

CHDI-00484077	HDAC	Neurological Disease
CHDI-00484077 (Compound 12) is a CNS-penetrant class IIa HDAC inhibitor, with IC₅₀s of 0.01 μM (HDAC4), 0.02 μM(HDAC5), 0.02 μM (HDAC7), 0.03 μM (HDAC9) respectively. CHDI-00484077 can be used for research of huntington’s disease .

HY-DY1024

TPE-MI (solution)	Huntingtin Parasite	Infection Neurological Disease
TPE-MI (Tetraphenylethene maleimide) (solution) is a thiol probe for measuring unfolded protein load and proteostasis in cells (the excitation wavelength is 350 nm and the emission wavelength is 470 nm). TPE-MI can report imbalances in proteostasis in induced pluripotent stem cell models of Huntington disease, as well as cells transfected with mutant Huntington exon 1 before the formation of visible aggregates. TPE-MI also detects protein damage following dihydroartemisinin research of the malaria parasitesPlasmodium falciparum . Solvent and concentration: DMSO: 10 mM

HY-40269

L-Pyroglutamic acid ethyl ester	Biochemical Assay Reagents Drug Intermediate	Neurological Disease
L-Pyroglutamic acid ethyl ester (Compound 2c) is an intermediate. L-Pyroglutamic acid ethyl ester is involved in the synthesis of γ-aminobutyrate transaminase inactivators. L-Pyroglutamic acid ethyl ester can be used in epilepsy and Huntington's disease research .

HY-125172

PolyQ aggregation inhibitor C2-8 Polyglutamine Aggregation inhibitor III	Huntingtin	Others
C2-8 is an inhibitor of polyglutamine (polyQ) aggregation (IC₅₀s=25 and 0.05 μM for recombinant HDQ51 and in PC12 cells, respectively). It also inhibits polyQ aggregation in organotypic hippocampal slice cultures isolated from R6/2 transgenic mice and reduces neurodegeneration in a dose-dependent manner in a Drosophila model of Huntington's disease. C2-8 (100 and 200 mg/kg) reduces huntingtin aggregate size, reduces neuronal atrophy, and improves motor performance in a rotarod test in the R6/2 transgenic mouse model of Huntington's disease.

HY-160604

Remacemide FPL 12924; PR 934-423; FPL 13592	iGluR	Neurological Disease
Remacemide (FPL 12924) is an orally active, non-competitive, low-affinity NMDA receptor antagonist. Remacemide shows neuroprotection activity in animal models of hypoxia and ischemic stroke. Remacemide is also an anticonvulsant, and can be used in Parkinson's disease and Huntington's disease research .

HY-153427

Tau protein aggregation-IN-1	Tau Protein	Neurological Disease
Tau protein aggregation-IN-1 (Compound 0c) is a Tau protein aggregation inhibitor. Tau protein aggregation-IN-1 can be used in the study of protein folding disorders such as Alzheimer's disease, dementia, Parkinson's disease, Huntington's disease and prion-based spongiform encephalopathies .

HY-15452R

Selisistat (Standard) EX-527 (Standard)	Sirtuin Reference Standards	Inflammation/Immunology Cancer
Selisistat (Standard) is the analytical standard of Selisistat. This product is intended for research and analytical applications. Selisistat (EX-527) is a potent and selective SirT1 (Sir2 in Drosophila melanogaster) inhibitor with an IC50 of 123 nM for SirT1. Selisistat alleviates pathology in multiple animal and cell models of Huntington's disease .

Cat. No.	Product Name

HY-L086

Neurodegenerative Disease-related Compound Library

3,545 compounds

Neurodegenerative diseases are incurable and life-threatening conditions that result in progressive degeneration and/or death of nerve cells. Some common neurodegenerative diseases include Alzheimer’s Disease (AD), Parkinson’s Disease (PD), Motor Neuron Disease (MND), Huntington’s Disease (HD), Spino-Cerebellar Ataxia (SCA), Spinal Muscular Atrophy (SMA), and Amyotrophic Lateral Sclerosis (ALS). Because the pathophysiology of neurodegenerative disorders is generally poorly understood, it is difficult to identify promising molecular targets and validate them. At the same time, about 85% of the drugs fail in clinical trials. Therefore, validating new targets and discovering new drugs to mitigate neurodegenerative disorders is need of the hour.

MCE offers a unique collection of 3,545 compounds with anti-Neurodegenerative Diseases activities or targeting the unique targets of neurodegenerative diseases. MCE Neurodegenerative Disease-related Compound Library is a useful tool for exploring the mechanism of neurodegenerative diseases and discovering new drugs for neurodegenerative diseases.

HY-L003

Apoptosis Compound Library

3,407 compounds

Apoptosis is an ordered and orchestrated cellular process that occurs in physiological and pathological conditions, which is also called programmed cell death (PCD). Apoptosis plays a crucial role in developing and maintaining the health of the body by eliminating old cells, unhealthy cells and unnecessary cells. Too little or too much apoptosis contribute to many diseases. When apoptosis does not work correctly, cells that should be eliminated may persist and become immortal, for example, in cancer and leukemia. When apoptosis works overly well, it kills too many cells and inflicts grave tissue damage. This is the case in strokes and neurodegenerative disorders such as Alzheimer's, Huntington's, and Parkinson's disease.

MCE designs a unique collection of 3,407 apoptosis-related compounds mainly focusing on the key targets in the apoptosis signaling pathway and can be used in the research of apoptosis signal pathway and related diseases.

Cat. No.	Product Name	Type

HY-143218

TPE-MI

10+ Cited Publications

Tetraphenylethene maleimide

Fluorescent Dye

TPE-MI (Tetraphenylethene maleimide) is a thiol probe for measuring unfolded protein load and proteostasis in cells (the excitation wavelength is 350 nm and the emission wavelength is 470 nm). TPE-MI can report imbalances in proteostasis in induced pluripotent stem cell models of Huntington disease, as well as cells transfected with mutant Huntington exon 1 before the formation of visible aggregates. TPE-MI also detects protein damage following dihydroartemisinin research of the malaria parasites Plasmodium falciparum .

HY-D0193A

Ponceau 4R (85%)

Acid Red 18 (85%); New Coccine (85%)

Fluorescent Dye

Ponceau 4R (85%) (Acid Red 18 (85%); New Coccine (85%)) is an orally active synthetic food colorant and a HSA-binding aggregator. Ponceau 4R (85%) binds to HSA, inducing its partial unfolding, conformational changes and aggregation. Ponceau 4R (85%) serves as a food colorant and can be used in research on diseases including type Ⅱ diabetes, Parkinson's disease, Huntington's disease and spongiform encephalopathy .

HY-DY1024

TPE-MI (solution)

Fluorescent Dye

TPE-MI (Tetraphenylethene maleimide) (solution) is a thiol probe for measuring unfolded protein load and proteostasis in cells (the excitation wavelength is 350 nm and the emission wavelength is 470 nm). TPE-MI can report imbalances in proteostasis in induced pluripotent stem cell models of Huntington disease, as well as cells transfected with mutant Huntington exon 1 before the formation of visible aggregates. TPE-MI also detects protein damage following dihydroartemisinin research of the malaria parasitesPlasmodium falciparum .
Solvent and concentration: DMSO: 10 mM

HY-150236

FITC-labeled Tominersen sodium	Fluorescent Dye
FITC-labeled Tominersen (sodium) is the Tominersen labeled with FITC. Tominersen (RG6042) is a second-generation 2′-O-(2-methoxyethyl) antisense oligonucleotide that targets huntingtin protein (HTT) mRNA and potently suppresses HTT production. Tominersen improves survival and reduces brain atrophy in mice. Tominersen can be used for the research of Huntington’s disease (HD).

Cat. No.	Product Name	Target	Research Area

HY-P6437A

Drp1 peptide inhibitor P110 TFA	Dynamin	Cardiovascular Disease Neurological Disease
Drp1 peptide inhibitor P110 (Compound P110) TFA is a selective Drp1 peptide inhibitor with neuroprotective properties. Drp1 peptide inhibitor P110 TFA can inhibit the activation of Drp1, prevent MPTP (HY-15608)-induced Drp1 mitochondrial translocation, and alleviate MPTP-induced dopaminergic neuron loss, dopaminergic nerve terminal damage, and behavioral deficits, and can be used in the study of Alzheimer's disease. Additionally, Drp1 peptide inhibitor P110 TFA can reduce mitochondrial damage and organ injury in animal models of Huntington's disease, cerebral ischemic injury, and myocardial infarction .

HY-P6374

IIQLPEIVVV TFA	Dynamin	Neurological Disease
IIQLPEIVVV TFA is a specific inhibitor of Drp1-Mff interaction. IIQLPEIVVV TFA can distinguish physiological from pathological fission and block physiological fission, thus leading to mitochondrial dysfunction. IIQLPEIVVV TFA can be used in the study of Huntington's disease .

HY-P6437

Drp1 peptide inhibitor P110	Dynamin	Cardiovascular Disease Neurological Disease
Drp1 peptide inhibitor P110 (Compound P110) is a selective Drp1 peptide inhibitor with neuroprotective properties. Drp1 peptide inhibitor P110 can inhibit the activation of Drp1, prevent MPTP-induced Drp1 mitochondrial translocation, and alleviate MPTP-induced dopaminergic neuron loss, dopaminergic nerve terminal damage, and behavioral deficits, and can be used in the study of Alzheimer's disease. Additionally, Drp1 peptide inhibitor P110 can reduce mitochondrial damage and organ injury in animal models of Huntington's disease, cerebral ischemic injury, and myocardial infarction .

HY-108312A

Ac-VEID-CHO TFA	Caspase	Neurological Disease
Ac-VEID-CHO (TFA) is a peptide-derived caspase inhibitor and has potency of inhibition for Caspase-6, Caspase-3 and Caspase-7 with IC₅₀ values of 16.2 nM, 13.6 nM and 162.1 nM, respectively. Ac-VEID-CHO (TFA) can be used for the research of neurodegenerative conditions including Alzheimer’s and Huntington’s disease .

HY-P11005

P259	Dynamin ATP Synthase	Neurological Disease
P259 is a Drp1-Mff inhibitor. P259 distinguishes physiological from pathological fission by specifically inhibiting Drp1-Mff interaction. P259 elongates cell mitochondria and disrupts mitochondrial function and motility. P259 reduces ATP levels and alters mitochondrial structure in the brain, resulting in behavioral deficits in wild-type mice and a short lifespan in Huntington's disease (HD) mice model .

HY-P10977

Tat-ASIC1a (1-20) (mouse, rat)	Sodium Channel RIP kinase	Neurological Disease
Tat-ASIC1a (1-20) (mouse, rat) is a competitive ASIC1a membrane-penetrating peptide. Tat-ASIC1a (1-20) (mouse, rat) has significantly neuroprotection effects, and reduces neuronal damage against acidotoxicity by targeting the ASIC1a-RIPK1 pathway and auto-inhibitory mechanism. Tat-ASIC1a (1-20) (mouse, rat) effectively protects brains from ischemic injury in ischemic stroke mice model. Tat-ASIC1a (1-20) (mouse, rat) can be used for neurodegenerative diseases research, such as Huntington disease and Parkinson’s disease .

HY-P10822

ED11	Caspase	Neurological Disease
ED11 is a potent and selective caspase-6 inhibitor with an IC₅₀ of 12.12 nM. ED11 competes with Htt for the caspase-6 active site, and thus reduce Htt cleavage. ED11 can cross the blood-brain barrier (BBB). ED11 has the potential for the study of Huntington's disease (HD) .

HY-180346

Hepta-histidine	Huntingtin	Neurological Disease
Hepta-histidine is an inhibitor of Ku70-Huntingtin protein interaction. Hepta-histidine can reverse the morphological abnormalities of primary neurons differentiatied from hiPSCs. Hepta-histidine prolongs the lifespan in severe Huntington’s disease R6/2 mouse model. Hepta-histidine ameliorates DNA damage in vitro. Hepta-histidine can be used to study anti-aggregation agent against Tau-associated neurodegenerative diseases such as Alzheimer’s disease and Huntington’s disease .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N10546

Ganglioside GM1	Structural Classification Natural Products Animals	iGluR Trk Receptor ERK Apoptosis Autophagy
Ganglioside GM1 is a type of glycosphingolipid, mainly found on the cell membranes of the central nervous system of vertebrates. Ganglioside GM1 exerts neuroprotective effects by reducing excessive activation of NMDAR, activating TrkA and ERK1/2, and inhibiting oxidative stress and cell apoptosis and autophagy. Ganglioside GM1 can be used in the research of diseases such as traumatic brain injury, Parkinson's disease, Alzheimer's disease, and Huntington's disease .

HY-N0576

Solanesol 2 Publications Verification	Other Terpenoids Structural Classification other families Neurological Disease Classification of Application Fields Terpenoids Plants Endogenous metabolite Inflammation/Immunology Disease Research Fields Source Classification	Endogenous Metabolite Heme Oxygenase (HO) HSP p38 MAPK Akt Apoptosis Caspase PARP
Solanesol is an orally active aliphatic terpene alcohol. Solanesol is mainly found in tobacco and other Solanaceae plants. Solanesol induces HO-1 and Hsp70 expression, activates p38 and Akt signaling pathways, and inhibits Apoptosis (reduces caspase-3 and PARP cleavage). Solanesol has antioxidant, anti-inflammatory, and neuroprotective activities. Solanesol can be used in the research of Huntington's disease, alcoholic liver disease, chronic inflammatory pain, anxiety, Alzheimer's disease, and bipolar disorder .

HY-16482

Teglicar 3 Publications Verification	Structural Classification Alkaloids Neurological Disease Classification of Application Fields Other Alkaloids Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Carnitine Palmitoyltransferase (CPT) Endogenous Metabolite
Teglicar is a selective and reversible orally active liver isoform of carnitine palmitoyl-transferase 1 (L-CPT1) inhibitor with an IC₅₀ value of 0.68 μM and a K_i value of 0.36 μM. Teglicar has a potential antihyperglycemic propert. Teglicar can be used for the research of diabetes and neurodegenerative disease including Huntington's disease (HD) .

HY-128700

Nicotinic acid mononucleotide 1 Publications Verification	Structural Classification Human Gut Microbiota Metabolites Classification of Application Fields Ketones, Aldehydes, Acids Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite Sirtuin
Nicotinic acid mononucleotide acts as a SARM1 inhibitor and a NAD ⁺ biosynthesis intermediate, with an IC₅₀ value of 93.3 μM against SARM1. Nicotinic acid mononucleotide exerts axon-protective effects, delays axonal degeneration, elevates NAD ⁺ levels, enhances Sirt1 activity, improves myocardial capillary density and alleviates myocardial fibrosis. Nicotinic acid mononucleotide reverses diabetic cardiomyopathy in diabetic mice by increasing myocardial NAD ⁺ levels. Nicotinic acid mononucleotide is applicable to research related to cancer, multiple sclerosis, diabetic cardiomyopathy, neurodegenerative diseases and Huntington's disease .

HY-N2099

Onjisaponin B 2 Publications Verification Senegin III	Triterpenes Structural Classification Neurological Disease Classification of Application Fields Terpenoids Polygalaceae Plants Polygala tenuifolia Willd. Disease Research Fields Source Classification	Autophagy Amyloid-β Caspase NF-κB Apoptosis
Onjisaponin B is an orally active natural product derived from Polygala tenuifolia. Onjisaponin B inhibits NF-κB p65. Onjisaponin B enhances autophagy and accelerates the degradation of mutant α-synuclein and huntingtin. Onjisaponin B reduces β-amyloid (Aβ) production. Onjisaponin B reduces radiation-induced cell apoptosis. Onjisaponin B has anti-oxidant and anti-inflammatory activities. Onjisaponin B can be used for neurological disease and radiation injury study, and its metabolite tenuifolin (TF) can enter the brain through the BBB .

HY-130259

LC3-mHTT-IN-AN2	other families Coumarins Phenols Polyphenols Phenylpropanoids Plants Source Classification	Atg8/LC3 Autophagy
LC3-mHTT-IN-AN2 (Compound AN2) is a mHTT-LC3 linker compound, which interacts with both mutant huntingtin protein (mHTT) and LC3B but not with wtHTT or irrelevant control proteins. LC3-mHTT-IN-AN2 reduces the levels of mHTT in an allele-selective manner in cultured Huntington disease (HD) mouse neurons .

HY-W010041

Scyllo-Inositol	Natural Products Endogenous metabolite Source Classification	α-synuclein Amyloid-β
Scyllo-Inositol is an inhibitor that targets the aggregation of misfolded proteins (such as α-synuclein and Amyloid-β), is orally effective, and can cross the blood-brain barrier. Scyllo-Inositol can selectively bind to and stabilize non-toxic oligomers, preventing them from converting into toxic fibers, exerting protein homeostasis regulation and neuroprotective activity. Scyllo-Inositol binds to the hydrophobic region of pathogenic proteins, inhibits protein aggregation, and promotes lysosome- and proteasome-mediated degradation pathways, thereby reducing neurotoxicity. Scyllo-Inositol can be used in the study of neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, and Huntington's disease .

HY-N2099A

(Z)-Onjisaponin B (Z)-Senegin III	Triterpenes Structural Classification Polygala senega L. Terpenoids Polygalaceae Plants Pentacyclic Triterpenoids Source Classification	Drug Derivative
(Z)-Onjisaponin B ((Z)-Senegin III) is a derivative of Onjisaponin B (HY-N2099). Onjisaponin B is an orally active natural product derived from Polygala tenuifolia. Onjisaponin B inhibits NF-κB p65. Onjisaponin B enhances autophagy and accelerates the degradation of mutant α-synuclein and huntingtin. Onjisaponin B reduces β-amyloid (Aβ) production. Onjisaponin B reduces radiation-induced cell apoptosis. Onjisaponin B has anti-oxidant and anti-inflammatory activities. Onjisaponin B can be used for neurological disease and radiation injury study, and its metabolite tenuifolin (TF) can enter the brain through the BBB .

HY-N0576R

Solanesol (Standard)	Structural Classification Natural Products other families Plants Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite Heme Oxygenase (HO) HSP p38 MAPK Akt Apoptosis Caspase PARP
Solanesol (Standard) is the analytical standard of Solanesol (HY-N0576). This product is intended for research and analytical applications. Solanesol is an orally active aliphatic terpene alcohol. Solanesol is mainly found in tobacco and other Solanaceae plants. Solanesol induces HO-1 and Hsp70 expression, activates p38 and Akt signaling pathways, and inhibits Apoptosis (reduces caspase-3 and PARP cleavage). Solanesol has antioxidant, anti-inflammatory, and neuroprotective activities. Solanesol can be used in the research of Huntington's disease, alcoholic liver disease, chronic inflammatory pain, anxiety, Alzheimer's disease, and bipolar disorder .

HY-W010041R

Scyllo-Inositol (Standard)	Structural Classification Natural Products Endogenous metabolite Source Classification	Reference Standards α-synuclein Amyloid-β
Scyllo-Inositol is an inhibitor that targets the aggregation of misfolded proteins (such as α-synuclein and Amyloid-β), is orally effective, and can cross the blood-brain barrier. Scyllo-Inositol can selectively bind to and stabilize non-toxic oligomers, preventing them from converting into toxic fibers, exerting protein homeostasis regulation and neuroprotective activity. Scyllo-Inositol binds to the hydrophobic region of pathogenic proteins, inhibits protein aggregation, and promotes lysosome- and proteasome-mediated degradation pathways, thereby reducing neurotoxicity. Scyllo-Inositol can be used in the study of neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, and Huntington's disease .

HY-N7773

Hibiscetin	Malvaceae Structural Classification Flavonols Flavonoids Hibiscus sabdariffa Linn. Plants Source Classification	TNF Receptor Interleukin Related Caspase SOD
Hibiscetin is an orally active anti-inflammatory, antioxidant, antihyperglycemic, hypolipidemic, hepatoprotective and neuroprotective agent. Hibiscetin reduces the levels of TNF-α, IL-1β and IL-6. Hibiscetin inhibits lipid peroxidation, reduces MDA levels, and induces the activities of antioxidant enzymes CAT, GSH and SOD. Hibiscetin lowers blood glucose, reverses reduced insulin levels, regulates adipokine levels, and reduces elevated AST and ALT levels. Hibiscetin alleviates Rotenone (HY-B1756)-induced akinesia and catalepsy, normalizes neurotransmitter levels, and modulates the activities of activated caspase 3 and BDNF. Hibiscetin can be used in the research of type 2 diabetes, Parkinson's disease and Huntington's disease .

Cat. No.	Product Name	Chemical Structure

HY-B0590S

Tetrabenazine-d6

Tetrabenazine-d₆ (Deutetrabenazine) is a deuterium-labled Tetrabenazine (HY-B0590). Tetrabenazine (Ro 1-9569) is a brain-penetrant and orally active VMAT2-selective ligand with human VMAT2 K_i 100 nM. Tetrabenazine binds VMAT2 to block monoamine uptake into synaptic vesicles, potentiates cytoplasmic monoamine degradation. Tetrabenazine weakly blocks dopamine D2 receptors, and increases dopamine turnover via elevated cerebrospinal fluid homovanillic acid. Tetrabenazine can be used for the research of Huntington’s disease, tardive dyskinesia, and Tourette’s syndrome .

HY-B1899S

Taurodeoxycholic acid-d5

Taurodeoxycholic acid-d₅ is the deuterium labeled Taurodeoxycholic acid (HY-B1899) . Taurodeoxycholic acid, a bile acid, stabilizes the mitochondrial membrane, decreases free radical formation. Taurodeoxycholic acid inhibits apoptosis by blocking a calcium-mediated apoptotic pathway as well as caspase-12 activation. Taurodeoxycholic acid exhibits neuroprotective effect in 3-nitropropionic acid induced mouse model or genetic mouse model of Huntington's disease (HD) .

HY-W777283

Idebenone-13C,d3

Idebenone- ¹³C,d₃ is the deuterium labeled and ¹³C-labeled Idebenone (HY-N0303). Idebenone, a well-appreciated mitochondrial protectant, exhibits protective efficacy against neurotoxicity and can be used for the research of Alzheimer's disease, Huntington's disease. Idebenone (oxidised form) has a dose-dependent inhibitory effect on the enzymatic metabolism of arachidonic acid in astroglial homogenates (IC₅₀=16.65 μM) . Idebenone, a coenzyme Q10 analog and an antioxidant, induces apoptotic cell death in the human dopaminergic neuroblastoma SHSY-5Y cells . Idebenone quickly crosses the blood-brain barrier.

HY-B0590S3

Tetrabenazine-d7

Tetrabenazine-d₇ (TBZ-d₇-d₇) is deuterium labeled Tetrabenazine (HY-B0590). Tetrabenazine (Ro 1-9569) is a brain-penetrant and orally active VMAT2-selective ligand with human VMAT2 K_i 100 nM. Tetrabenazine binds VMAT2 to block monoamine uptake into synaptic vesicles, potentiates cytoplasmic monoamine degradation. Tetrabenazine weakly blocks dopamine D2 receptors, and increases dopamine turnover via elevated cerebrospinal fluid homovanillic acid. Tetrabenazine can be used for the research of Huntington’s disease, tardive dyskinesia, and Tourette’s syndrome .

HY-W020050S

Cystamine-d8 dihydrochloride

Cystamine-d₈ (dihydrochloride） is the deuterium labeled Cystamine (dihydrochloride） . Cystamine (dihydrochloride) is the disulfide form of the free thiol, cysteamine. Cystamine is an orally active transglutaminase (Tgase) inhibitor. Cystamine also has inhibition activity for caspase-3 with an IC₅₀ value of 23.6 μM. Cystamine can be used for the research of severals diseases including Huntington's disease (HD) .

HY-12542S

Dantrolene-13C3

Dantrolene- ¹³C₃ is the ¹³C₃ labeled Dantrolene. Dantrolene (F368), a muscle relaxant, non-competitively inhibits human erythrocyte glutathione reductase. Ki and IC50 values are 111.6 μM and 52.3 μM, respectively. Dantrolene is a ryanodine receptor antagonist and Ca2+ signaling stabilizer. Dantrolene can be used for the research of muscle spasticity, malignant hyperthermia, Huntington's disease and other neuroleptic malignant syndrome.

HY-W653989

Desonide-13C3

Desonide- ¹³C₃ is the ¹³C labeled isotope of Desonide (HY-B0248). Desonide is a non-fluorinated corticosteroid anti-inflammatory agent that acts on the glucocorticoid receptor. Desonide can also specifically bind to the mutant huntingtin protein (mHTT), reducing the level and toxicity of mHTT. Desonide can be used in the research of Huntington's disease and inflammatory diseases such as atopic dermatitis .

HY-W707693

Scyllo-Inositol-d6

Scyllo-Inositol-d₆ is the deuterium labeled Scyllo-Inositol (HY-W010041). Scyllo-Inositol is an inhibitor that targets the aggregation of misfolded proteins (such as α-synuclein and Amyloid-β), is orally effective, and can cross the blood-brain barrier. Scyllo-Inositol can selectively bind to and stabilize non-toxic oligomers, preventing them from converting into toxic fibers, exerting protein homeostasis regulation and neuroprotective activity. Scyllo-Inositol binds to the hydrophobic region of pathogenic proteins, inhibits protein aggregation, and promotes lysosome- and proteasome-mediated degradation pathways, thereby reducing neurotoxicity. Scyllo-Inositol can be used in the study of neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, and Huntington's disease .

HY-B0696S

Tiagabine-d6

Tiagabine-d₆ (NO050328-d₆) is deuterium labeled Tiagabine. Tiagabine (NO050328; NO328; TGB) is an orally active, highly selective, and reversible GAT-1 inhibitor and anticonvulsant that crosses the blood-brain barrier. By blocking the reuptake of GABA in neurons and glial cells, tiagabine increases extracellular GABA levels to enhance inhibitory signal transduction, thereby exerting multiple activities such as anticonvulsant, neuroprotective, and antioxidant effects. Tiagabine exhibits linear pharmacokinetic properties. Although it is metabolized by CYP3A and has a high protein binding rate, it carries a low risk of cognitive impairment. Tiagabine is widely used in research on related diseases including epilepsy (including refractory partial seizures), alcohol withdrawal symptoms, and Huntington's disease .

HY-B0696AS

Tiagabine-d4 hydrochloride

Tiagabine-d₄ hydrochloride is deuterated labeled Tiagabine hydrochloride (HY-B0696A). Tiagabine hydrochloride (NO050328; NO328; TGB) is an orally active, highly selective, and reversible GAT-1 inhibitor and anticonvulsant that crosses the blood-brain barrier. By blocking the reuptake of GABA in neurons and glial cells, tiagabine increases extracellular GABA levels to enhance inhibitory signal transduction, thereby exerting multiple activities such as anticonvulsant, neuroprotective, and antioxidant effects. Tiagabine hydrochloride exhibits linear pharmacokinetic properties. Although it is metabolized by CYP3A and has a high protein binding rate, it carries a low risk of cognitive impairment. Tiagabine hydrochloride is widely used in research on related diseases including epilepsy (including refractory partial seizures), alcohol withdrawal symptoms, and Huntington's disease .

HY-158252S

Tiagabine-d5 hydrochloride

Tiagabine-d₅ (hydrochloride) is deuterium labeled Tiagabine (hydrochloride). Tiagabine hydrochloride (NO050328; NO328; TGB) is an orally active, highly selective, and reversible GAT-1 inhibitor and anticonvulsant that crosses the blood-brain barrier. By blocking the reuptake of GABA in neurons and glial cells, tiagabine increases extracellular GABA levels to enhance inhibitory signal transduction, thereby exerting multiple activities such as anticonvulsant, neuroprotective, and antioxidant effects. Tiagabine hydrochloride exhibits linear pharmacokinetic properties. Although it is metabolized by CYP3A and has a high protein binding rate, it carries a low risk of cognitive impairment. Tiagabine hydrochloride is widely used in research on related diseases including epilepsy (including refractory partial seizures), alcohol withdrawal symptoms, and Huntington's disease .

HY-B0696S1

Tiagabine-d4

Tiagabine-d₄ (NO050328-d₄) is deuterium labeled Tiagabine. Tiagabine (NO050328; NO328; TGB) is an orally active, highly selective, and reversible GAT-1 inhibitor and anticonvulsant that crosses the blood-brain barrier. By blocking the reuptake of GABA in neurons and glial cells, tiagabine increases extracellular GABA levels to enhance inhibitory signal transduction, thereby exerting multiple activities such as anticonvulsant, neuroprotective, and antioxidant effects. Tiagabine exhibits linear pharmacokinetic properties. Although it is metabolized by CYP3A and has a high protein binding rate, it carries a low risk of cognitive impairment. Tiagabine is widely used in research on related diseases including epilepsy (including refractory partial seizures), alcohol withdrawal symptoms, and Huntington's disease .

Cat. No.	Product Name		Classification

HY-142035

N-Propargylglycine 1 Publications Verification		Alkynes
N-Propargylglycine is a brain-penetrant and orally active PRODH inhibitor. N-Propargylglycine covalently modifies enzyme-bound FAD and active site lysine, causing enzyme structural distortion, protein decay, and irreversible inhibition of proline and 4-hydroxyproline catabolism. N-Propargylglycine induces UPRmt, upregulates mitochondrial chaperones and YME1L1, enhances mitochondrial proteostasis, blocks astrocytic L-proline consumption, and abolishes L-proline’s ATP-maintaining and viability-protective effects. N-Propargylglycine stimulates neural processes, increases brain proline, hydroxyproline, and sarcosine levels, partially normalizes Huntington’s disease whole brain transcriptomes. N-Propargylglycine reduces hyperoxaluria, prevents calcium oxalate stone formation, reduces kidney tubular damage, and restores weight and survival in Grhpr knockout mice. N-Propargylglycine can be used for the research of breast cancer, neurodegenerative disorders, Huntington’s disease, and primary hyperoxaluria type 2 .

Cat. No.	Product Name		Classification

HY-16482

Teglicar 3 Publications Verification		Cationic Lipids
Teglicar is a selective and reversible orally active liver isoform of carnitine palmitoyl-transferase 1 (L-CPT1) inhibitor with an IC₅₀ value of 0.68 μM and a K_i value of 0.36 μM. Teglicar has a potential antihyperglycemic propert. Teglicar can be used for the research of diabetes and neurodegenerative disease including Huntington's disease (HD) .

HY-132579

Tominersen RG6042; IONIS-HTTRx		Antisense Oligonucleotides
Tominersen (RG6042) is a second-generation 2′-O-(2-methoxyethyl) antisense oligonucleotide that targets huntingtin protein (HTT) mRNA and potently suppresses HTT production. Tominersen improves survival and reduces brain atrophy in mice. Tominersen can be used for the research of Huntington’s disease (HD) .

HY-132579A

Tominersen sodium RG6042 sodium; IONIS-HTTRx sodium		Antisense Oligonucleotides
Tominersen sodium is a second-generation 2′-O-(2-methoxyethyl) antisense oligonucleotide that targets huntingtin protein (HTT) mRNA and potently suppresses HTT production. Tominersen improves survival and reduces brain atrophy in mice. Tominersen sodium can be used for the research of Huntington’s disease (HD) .

HY-132593

Rovanersen WVE-120101		Antisense Oligonucleotides
Rovanersen (WVE-120101) is an antisense oligonucleotide that specifically targets mutated mRNA copies of the huntington (HTT) gene without affecting healthy mRNA of HTT gene, thereby preventing the production of faulty Huntingtin protein. Rovanersen can be used for huntington’s disease research .

HY-132593A

Rovanersen sodium WVE-120101 sodium		Antisense Oligonucleotides
Rovanersen sodium is an antisense oligonucleotide that specifically targets mutated mRNA copies of the huntington (HTT) gene without affecting healthy mRNA of HTT gene, thereby preventing the production of faulty Huntingtin protein. Rovanersen sodium can be used for huntington’s disease research .

HY-150236

FITC-labeled Tominersen sodium		Antisense Oligonucleotides
FITC-labeled Tominersen (sodium) is the Tominersen labeled with FITC. Tominersen (RG6042) is a second-generation 2′-O-(2-methoxyethyl) antisense oligonucleotide that targets huntingtin protein (HTT) mRNA and potently suppresses HTT production. Tominersen improves survival and reduces brain atrophy in mice. Tominersen can be used for the research of Huntington’s disease (HD).

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Huntington

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

NaturalProducts

Isotope-Labeled Compounds

Click Chemistry

Oligonucleotides

Natural
Products